Research & Pharma Services
Antibiotic discovery and bacterial metabolism research
Key Facts
About Resistell
Resistell is an EPFL spin-off and private diagnostics company based in Basel, Switzerland, focused on addressing the global crisis of antimicrobial resistance. Its core innovation is a nanomotion-based platform that detects bacterial metabolic activity to determine antibiotic susceptibility within one hour, a significant improvement over standard culture-based methods that take 24-48 hours. The company has validated its technology through peer-reviewed publication in Nature Communications, initiated international clinical studies, and formed strategic partnerships with hospitals and foundations. Resistell is positioned in the high-growth AST market, aiming to reduce inappropriate antibiotic use, lower healthcare costs, and save lives.
View full company profile